Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tardive dyskinesia
Pharma
Neurocrine's Ingrezza nabs Huntington's nod to rival Austedo
Neurocrine Biosciences’ Ingrezza is debuting in a treatment area with hundreds of millions of dollars of revenue potential.
Fraiser Kansteiner
Aug 22, 2023 9:53am
Teva's flagship drug Austedo scores new approval at the FDA
Feb 21, 2023 4:28pm
Teva's Austedo carries blockbuster expectations into 2022
Feb 9, 2022 9:49am
Teva's Austedo struggling from pandemic slowdown; All eyes on Q4
Oct 27, 2021 11:46am
Neurocrine raises a monument to mental health
Oct 8, 2021 9:40am
Teva launches first DTC for Austedo into competitive market
May 28, 2021 7:20am